Sale and use of Nizoral against fungal infections barred

By
November 8, 2013 20:03
1 minute read.

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

The Health Ministry has decided to bar the sale of a common and veteran drug taken orally for fungal infections. The use of oral Nizoral tablets containing the active substance called ketoconazole will be prohibited, the ministry announced on Friday, following a decision to that effect by the European Medicines Agency’s Committee on Medicinal Products for Human Use.

Other drugs considered less toxic and generally more effective are triazole antifungal agents such as fluconazole and itraconazole, which are usually preferred for internal use.

Ketoconazole is now believed to pose the possibility of serious damage to the liver -- even to require a liver transplant -- and death.

Nizoral cream and shampoo whose active ingredient is not ingested will be permitted however, the ministry said, because the amount that reaches body systems is minimal.

The Europeans said that “no use of the oral drug justifies the dangers of taking it.” In the US, however, the FDA did not prohibit the marketing and prescription of the drug but merely restricted it except for except for treating severe conditions for which there is no effective alternative medication. The Health Ministry decided to follow the path of the Europeans and not the Americans.

Patients in Israel who have been prescribed oral medications with ketoconazole should consult with their doctors about finding a replacement therapy.

Related Content

Breaking news
August 16, 2018
Report: Saudi banks see no significant impact from lira depreciation

By REUTERS